Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Amy Ives
Observed names:
A. Ives,
Ives, Amy
Institution:
Royal Brisbane and Women's Hospital
Observed institution:
Royal Brisbane and Women's Hospital
ORCID:
0000-0002-7023-7578
Observed ORCID:
0000-0002-7023-7578
OpenAlex ID:
A5081290374
Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
·
Molecular Cancer Therapeutics
·
11
PDF
Resilience and ongoing quality care for cancer clinical trials during COVID‐19: Experience from a tertiary hospital in Australia
2021
·
Amy Ives
, Tricia Pusztai
, et al.
·
Asia-Pacific Journal of Clinical Oncology
·
8
PDF
Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial
2026
·
Elizabeth Ahern
, Cassie Turner
, et al.
·
Asia-Pacific Journal of Clinical Oncology
·
1
Targeting PD-L2–galectin-9 interactions restores immunity in cancer and infectious diseases
2026
·
Liu, Ji
, Deshapriya, Karunarathne
, et al.
·
Zenodo (CERN European Organization for Nuclear Research)
Abstract PS2-10-02: Liquid Biopsy Tracking of PI3K-mTOR Residual Disease Signatures in Metastatic Breast Cancer
2026
·
M. Melino
, W. Tu
, et al.
·
Clinical Cancer Research
Supplementary Results from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
Supplementary Figure 5 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 4 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Data from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
Supplementary Table S3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Methods from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
Supplementary Figure 3 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 6 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Figure 7 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Table S2 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Supplementary Table S1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer
2025
·
Michelle Melino
, Wen Juan Tu
, et al.
PDF
Show more works
View as search
Works count:
18
Citation count:
20
H-index:
2
I10-index:
1
Year
Topic
Type